Xenon Pharmaceuticals Inc.
Clinical trials sponsored by Xenon Pharmaceuticals Inc., explained in plain language.
Xenon Pharmaceuticals Inc.
XENE
NASDAQ
A clinical-stage biopharmaceutical company developing neurology therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could tame focal seizures when other drugs fail Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New depression drug tested for Long-Term safety and effectiveness Results expected Jan 2027 (estimated) May already have reported ↗
- New seizure drug shows promise in late-stage trial Results expected Apr 2027 (estimated)
- New depression pill could lift the fog: phase 3 trial underway Results expected May 2027 (estimated) May already have reported ↗ 🚀 Make-or-break